ID   OGA_HUMAN               Reviewed;         916 AA.
AC   O60502; B7WPB9; D3DR79; E9PGF9; O75166; Q86WV0; Q8IV98; Q9BVA5; Q9HAR0;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 2.
DT   10-FEB-2021, entry version 168.
DE   RecName: Full=Protein O-GlcNAcase {ECO:0000303|PubMed:11148210, ECO:0000303|PubMed:11788610, ECO:0000305};
DE            Short=OGA {ECO:0000303|PubMed:20863279};
DE            EC=3.2.1.169 {ECO:0000269|PubMed:11148210, ECO:0000269|PubMed:11788610, ECO:0000269|PubMed:18586680, ECO:0000269|PubMed:20863279, ECO:0000269|PubMed:22365600, ECO:0000305|PubMed:20673219};
DE   AltName: Full=Beta-N-acetylglucosaminidase {ECO:0000303|PubMed:11148210};
DE   AltName: Full=Beta-N-acetylhexosaminidase;
DE   AltName: Full=Beta-hexosaminidase;
DE   AltName: Full=Meningioma-expressed antigen 5 {ECO:0000303|PubMed:9811929};
DE   AltName: Full=N-acetyl-beta-D-glucosaminidase;
DE   AltName: Full=N-acetyl-beta-glucosaminidase;
DE   AltName: Full=Nuclear cytoplasmic O-GlcNAcase and acetyltransferase;
DE            Short=NCOAT;
GN   Name=OGA {ECO:0000312|HGNC:HGNC:7056, ECO:0000303|Ref.3};
GN   Synonyms=HEXC, KIAA0679, MEA5,
GN   MGEA5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Meningioma;
RX   PubMed=9811929; DOI=10.1093/hmg/7.12.1859;
RA   Heckel D., Comtesse N., Brass N., Blin N., Zang K.D., Meese E.;
RT   "Novel immunogenic antigen homologous to hyaluronidase in meningioma.";
RL   Hum. Mol. Genet. 7:1859-1872(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 3), SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=11341771; DOI=10.1006/bbrc.2001.4815;
RA   Comtesse N., Maldener E., Meese E.;
RT   "Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase
RT   and a beta-N-acetylglucosaminidase.";
RL   Biochem. Biophys. Res. Commun. 283:634-640(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain;
RX   PubMed=11148210; DOI=10.1074/jbc.m010420200;
RA   Gao Y., Wells L., Comer F.I., Parker G.J., Hart G.W.;
RT   "Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and
RT   characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from
RT   human brain.";
RL   J. Biol. Chem. 276:9838-9845(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LYS-602.
RC   TISSUE=Cervix, Eye, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, PTM,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=11788610; DOI=10.1074/jbc.m109656200;
RA   Wells L., Gao Y., Mahoney J.A., Vosseller K., Chen C., Rosen A., Hart G.W.;
RT   "Dynamic O-glycosylation of nuclear and cytosolic proteins: further
RT   characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-
RT   GlcNAcase.";
RL   J. Biol. Chem. 277:1755-1761(2002).
RN   [10]
RP   ACTIVE SITE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-174 AND ASP-175.
RX   PubMed=16533067; DOI=10.1021/bi052370b;
RA   Cetinbas N., Macauley M.S., Stubbs K.A., Drapala R., Vocadlo D.J.;
RT   "Identification of Asp174 and Asp175 as the key catalytic residues of human
RT   O-GlcNAcase by functional analysis of site-directed mutants.";
RL   Biochemistry 45:3835-3844(2006).
RN   [11]
RP   PTM, SITE, MUTAGENESIS OF ASP-413, AND CATALYTIC ACTIVITY.
RX   PubMed=18586680; DOI=10.1074/jbc.m804116200;
RA   Butkinaree C., Cheung W.D., Park S., Park K., Barber M., Hart G.W.;
RT   "Characterization of beta-N-acetylglucosaminidase cleavage by caspase-3
RT   during apoptosis.";
RL   J. Biol. Chem. 283:23557-23566(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF TYR-69; ASP-175; VAL-255;
RP   TYR-286; ASP-287 AND TRP-679.
RX   PubMed=20863279; DOI=10.1042/bj20101338;
RA   Schimpl M., Schuttelkopf A.W., Borodkin V.S., van Aalten D.M.;
RT   "Human OGA binds substrates in a conserved peptide recognition groove.";
RL   Biochem. J. 432:1-7(2010).
RN   [16]
RP   FUNCTION OF ISOFORMS 1 AND 3, AND CATALYTIC ACTIVITY.
RX   PubMed=20673219; DOI=10.1134/s0006297910070175;
RA   Li J., Huang C.L., Zhang L.W., Lin L., Li Z.H., Zhang F.W., Wang P.;
RT   "Isoforms of human O-GlcNAcase show distinct catalytic efficiencies.";
RL   Biochemistry (Mosc.) 75:938-943(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   LACK OF ACETYLTRANSFERASE ACTIVITY, AND FUNCTION.
RX   PubMed=24088714; DOI=10.1098/rsob.130021;
RA   Rao F.V., Schuttelkopf A.W., Dorfmueller H.C., Ferenbach A.T.,
RA   Navratilova I., van Aalten D.M.;
RT   "Structure of a bacterial putative acetyltransferase defines the fold of
RT   the human O-GlcNAcase C-terminal domain.";
RL   Open Biol. 3:130021-130021(2013).
RN   [23]
RP   INTERACTION WITH HUMAN T-CELL LEUKEMIA VIRUS 1/HTLV-1 PROTEIN TAX.
RX   PubMed=28742148; DOI=10.1371/journal.ppat.1006518;
RA   Groussaud D., Khair M., Tollenaere A.I., Waast L., Kuo M.S., Mangeney M.,
RA   Martella C., Fardini Y., Coste S., Souidi M., Benit L., Pique C., Issad T.;
RT   "Hijacking of the O-GlcNAcZYME complex by the HTLV-1 Tax oncoprotein
RT   facilitates viral transcription.";
RL   PLoS Pathog. 13:E1006518-E1006518(2017).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 402-408, MUTAGENESIS OF TYR-69,
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22365600; DOI=10.1016/j.chembiol.2012.01.011;
RA   Schimpl M., Borodkin V.S., Gray L.J., van Aalten D.M.;
RT   "Synergy of peptide and sugar in O-GlcNAcase substrate recognition.";
RL   Chem. Biol. 19:173-178(2012).
CC   -!- FUNCTION: [Isoform 1]: Cleaves GlcNAc but not GalNAc from O-
CC       glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc and 4-
CC       methylumbelliferone-GlcNAc as substrates but not p-nitrophenyl-beta-
CC       GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro) (PubMed:11148210). Does
CC       not bind acetyl-CoA and does not have histone acetyltransferase
CC       activity (PubMed:24088714). {ECO:0000269|PubMed:11148210,
CC       ECO:0000269|PubMed:11788610, ECO:0000269|PubMed:20673219,
CC       ECO:0000269|PubMed:22365600, ECO:0000269|PubMed:24088714}.
CC   -!- FUNCTION: [Isoform 3]: Cleaves GlcNAc but not GalNAc from O-
CC       glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc as substrate
CC       but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in
CC       vitro), but has about six times lower specific activity than isoform 1.
CC       {ECO:0000269|PubMed:20673219}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-O-(N-acetyl-beta-D-glucosaminyl)-L-seryl-[protein] + H2O =
CC         L-seryl-[protein] + N-acetyl-D-glucosamine; Xref=Rhea:RHEA:48876,
CC         Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:12251, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:29999, ChEBI:CHEBI:90838, ChEBI:CHEBI:506227;
CC         EC=3.2.1.169; Evidence={ECO:0000269|PubMed:11148210,
CC         ECO:0000269|PubMed:11788610, ECO:0000269|PubMed:18586680,
CC         ECO:0000269|PubMed:20863279, ECO:0000269|PubMed:22365600,
CC         ECO:0000305|PubMed:20673219};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-O-(N-acetyl-beta-D-glucosaminyl)-L-threonyl-[protein] + H2O
CC         = L-threonyl-[protein] + N-acetyl-D-glucosamine;
CC         Xref=Rhea:RHEA:48892, Rhea:RHEA-COMP:11060, Rhea:RHEA-COMP:12252,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:90840,
CC         ChEBI:CHEBI:506227; EC=3.2.1.169;
CC         Evidence={ECO:0000269|PubMed:11148210, ECO:0000269|PubMed:11788610,
CC         ECO:0000269|PubMed:18586680, ECO:0000269|PubMed:20863279,
CC         ECO:0000269|PubMed:22365600, ECO:0000305|PubMed:20673219};
CC   -!- ACTIVITY REGULATION: Inhibited by N-acetylglucosamine and not N-
CC       acetylgalactosamine. {ECO:0000269|PubMed:11148210}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.1 mM for pNP-GlcNAc {ECO:0000269|PubMed:11788610};
CC         Vmax=652 umol/min/mg enzyme with pNP-GLcNAc as substrate
CC         {ECO:0000269|PubMed:11788610};
CC       pH dependence:
CC         Optimum pH is 5.7-7. {ECO:0000269|PubMed:11148210};
CC   -!- SUBUNIT: Monomer (PubMed:11788610). Interacts with CLOCK (By
CC       similarity). {ECO:0000250|UniProtKB:Q9EQQ9,
CC       ECO:0000269|PubMed:11788610}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human T-cell leukemia
CC       virus 1/HTLV-1 protein Tax; this interaction increases Tax interacting
CC       partner CREB1 O-GlcNAcylation. {ECO:0000269|PubMed:28742148}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus
CC       {ECO:0000269|PubMed:11341771}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19923450,
CC       ECO:0000269|PubMed:3753689, ECO:0000269|PubMed:3754863}. Mitochondrion
CC       {ECO:0000269|PubMed:19923450}. Nucleus {ECO:0000269|PubMed:19923450,
CC       ECO:0000269|PubMed:3753689}. Microsome {ECO:0000269|PubMed:19923450}.
CC       Endoplasmic reticulum {ECO:0000269|PubMed:19923450}. Secreted
CC       {ECO:0000250}. Note=Associated with different subcellular fractions
CC       such as mitochondrial, nuclear, and rough/smooth microsomal fractions.
CC       {ECO:0000269|PubMed:19923450}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O60502-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O60502-2; Sequence=VSP_020866, VSP_020869;
CC       Name=3; Synonyms=MGEA5s;
CC         IsoId=O60502-3; Sequence=VSP_020867, VSP_020868;
CC       Name=4;
CC         IsoId=O60502-4; Sequence=VSP_020866;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Shows highest expression in the brain,
CC       placenta and pancreas. {ECO:0000269|PubMed:11148210,
CC       ECO:0000269|PubMed:11341771}.
CC   -!- PTM: Proteolytically cleaved by caspase-3 during apoptosis. The
CC       fragments interact with each other; cleavage does not decrease enzyme
CC       activity. {ECO:0000269|PubMed:11788610, ECO:0000269|PubMed:18586680}.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 84 family. {ECO:0000305}.
CC   -!- CAUTION: The mouse and rat orthologs were initially identified as bi-
CC       functional proteins containing an N-terminal domain with O-GlcNAcase
CC       activity and a C-terminal domain with histone acetyltransferase
CC       activity. The histone acetyltransferase activity was detected only when
CC       the protein was expressed in mammalian cells, but not when expressed in
CC       bacterial cells, suggesting that the histone acetyltransferase activity
CC       might be due to the presence of a contaminant. Comparison of the human
CC       protein with a bacterial putative acetyltransferase (AC Q2CEE2) shows
CC       that the residues important for acetyl-CoA binding are not conserved,
CC       and that the residues proposed to be important for histone
CC       acetyltransferase activity are not in a position where they could
CC       participate in catalysis. Characterization of the human protein shows
CC       that it does not bind acetyl-CoA and therefore cannot have
CC       acetyltransferase activity. {ECO:0000269|PubMed:24088714,
CC       ECO:0000305|PubMed:24088714}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH47877.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAA31654.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF036144; AAD05385.2; -; mRNA.
DR   EMBL; AF307332; AAG21428.1; -; mRNA.
DR   EMBL; AB014579; BAA31654.2; ALT_INIT; mRNA.
DR   EMBL; AC010789; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49744.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49741.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49742.1; -; Genomic_DNA.
DR   EMBL; BC001343; AAH01343.1; -; mRNA.
DR   EMBL; BC039583; AAH39583.2; -; mRNA.
DR   EMBL; BC047877; AAH47877.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS44471.1; -. [O60502-4]
DR   CCDS; CCDS7520.1; -. [O60502-1]
DR   PIR; T00360; T00360.
DR   RefSeq; NP_001135906.1; NM_001142434.1. [O60502-4]
DR   RefSeq; NP_036347.1; NM_012215.3. [O60502-1]
DR   PDB; 2YDQ; X-ray; 2.60 A; T=402-408.
DR   PDB; 5M7R; X-ray; 2.35 A; A/B=1-916.
DR   PDB; 5M7S; X-ray; 2.40 A; A/B=1-916.
DR   PDB; 5M7T; X-ray; 2.60 A; A/B=1-916.
DR   PDB; 5M7U; X-ray; 2.30 A; A/B=1-916.
DR   PDB; 5TKE; X-ray; 2.48 A; A/B=60-400, A/B=553-704.
DR   PDB; 5UHK; X-ray; 2.97 A; A/C=56-400, B/D=544-705.
DR   PDB; 5UHL; X-ray; 3.14 A; A/C=56-400, B/D=544-705.
DR   PDB; 5UHO; X-ray; 3.21 A; A/C=56-400, B/D=544-705.
DR   PDB; 5UHP; X-ray; 2.79 A; A/B/C/D=14-400, E/F/G/H=554-705.
DR   PDB; 5UN8; X-ray; 2.13 A; A/B/C/D=60-400, A/B/C/D=553-704.
DR   PDB; 5UN9; X-ray; 2.50 A; A/B=60-400, A/B=553-704.
DR   PDB; 5VVO; X-ray; 2.60 A; A/B=60-400, A/B=553-704.
DR   PDB; 5VVT; X-ray; 2.80 A; A/C=60-400, A/C=553-704.
DR   PDB; 5VVU; X-ray; 2.70 A; A/C=60-400, A/C=553-704.
DR   PDB; 5VVV; X-ray; 2.80 A; A/C=60-400, A/C=553-704.
DR   PDB; 5VVX; X-ray; 2.90 A; A/C=60-400, A/C=553-704.
DR   PDB; 6HKI; X-ray; 3.30 A; A/B=1-916.
DR   PDB; 6PM9; X-ray; 2.86 A; A/B/C/D=14-400, E/F/G/H=553-705.
DR   PDBsum; 2YDQ; -.
DR   PDBsum; 5M7R; -.
DR   PDBsum; 5M7S; -.
DR   PDBsum; 5M7T; -.
DR   PDBsum; 5M7U; -.
DR   PDBsum; 5TKE; -.
DR   PDBsum; 5UHK; -.
DR   PDBsum; 5UHL; -.
DR   PDBsum; 5UHO; -.
DR   PDBsum; 5UHP; -.
DR   PDBsum; 5UN8; -.
DR   PDBsum; 5UN9; -.
DR   PDBsum; 5VVO; -.
DR   PDBsum; 5VVT; -.
DR   PDBsum; 5VVU; -.
DR   PDBsum; 5VVV; -.
DR   PDBsum; 5VVX; -.
DR   PDBsum; 6HKI; -.
DR   PDBsum; 6PM9; -.
DR   SMR; O60502; -.
DR   BioGRID; 115948; 44.
DR   IntAct; O60502; 34.
DR   MINT; O60502; -.
DR   STRING; 9606.ENSP00000354850; -.
DR   BindingDB; O60502; -.
DR   ChEMBL; CHEMBL5921; -.
DR   DrugBank; DB00428; Streptozocin.
DR   GuidetoPHARMACOLOGY; 3101; -.
DR   CAZy; GH84; Glycoside Hydrolase Family 84.
DR   GlyGen; O60502; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O60502; -.
DR   MetOSite; O60502; -.
DR   PhosphoSitePlus; O60502; -.
DR   SwissPalm; O60502; -.
DR   BioMuta; MGEA5; -.
DR   CPTAC; CPTAC-1223; -.
DR   EPD; O60502; -.
DR   jPOST; O60502; -.
DR   MassIVE; O60502; -.
DR   MaxQB; O60502; -.
DR   PaxDb; O60502; -.
DR   PeptideAtlas; O60502; -.
DR   PRIDE; O60502; -.
DR   ProteomicsDB; 20314; -.
DR   ProteomicsDB; 49438; -. [O60502-1]
DR   ProteomicsDB; 49439; -. [O60502-2]
DR   ProteomicsDB; 49440; -. [O60502-3]
DR   Antibodypedia; 31340; 166 antibodies.
DR   DNASU; 10724; -.
DR   Ensembl; ENST00000357797; ENSP00000350445; ENSG00000198408. [O60502-2]
DR   Ensembl; ENST00000361464; ENSP00000354850; ENSG00000198408. [O60502-1]
DR   Ensembl; ENST00000370094; ENSP00000359112; ENSG00000198408. [O60502-3]
DR   Ensembl; ENST00000439817; ENSP00000409973; ENSG00000198408. [O60502-4]
DR   GeneID; 10724; -.
DR   KEGG; hsa:10724; -.
DR   UCSC; uc001ktv.3; human. [O60502-1]
DR   CTD; 10724; -.
DR   DisGeNET; 10724; -.
DR   GeneCards; OGA; -.
DR   HGNC; HGNC:7056; OGA.
DR   HPA; ENSG00000198408; Low tissue specificity.
DR   MIM; 604039; gene.
DR   neXtProt; NX_O60502; -.
DR   OpenTargets; ENSG00000198408; -.
DR   PharmGKB; PA30787; -.
DR   VEuPathDB; HostDB:ENSG00000198408.13; -.
DR   eggNOG; KOG3698; Eukaryota.
DR   GeneTree; ENSGT00390000007726; -.
DR   HOGENOM; CLU_009837_1_0_1; -.
DR   InParanoid; O60502; -.
DR   OMA; QFGCEAY; -.
DR   OrthoDB; 159999at2759; -.
DR   PhylomeDB; O60502; -.
DR   TreeFam; TF313732; -.
DR   BioCyc; MetaCyc:HS03036-MONOMER; -.
DR   BRENDA; 3.2.1.35; 2681.
DR   PathwayCommons; O60502; -.
DR   BioGRID-ORCS; 10724; 97 hits in 881 CRISPR screens.
DR   ChiTaRS; MGEA5; human.
DR   GeneWiki; MGEA5; -.
DR   GenomeRNAi; 10724; -.
DR   Pharos; O60502; Tchem.
DR   PRO; PR:O60502; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; O60502; protein.
DR   Bgee; ENSG00000198408; Expressed in forebrain and 244 other tissues.
DR   ExpressionAtlas; O60502; baseline and differential.
DR   Genevisible; O60502; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0102167; F:[protein]-3-O-(N-acetyl-D-glucosaminyl)-L-serine O-N-acetyl-alpha-D-glucosaminase activity; IEA:UniProtKB-EC.
DR   GO; GO:0102571; F:[protein]-3-O-(N-acetyl-D-glucosaminyl)-L-serine/L-threonine O-N-acetyl-alpha-D-glucosaminase activity; IEA:UniProtKB-EC.
DR   GO; GO:0102166; F:[protein]-3-O-(N-acetyl-D-glucosaminyl)-L-threonine O-N-acetyl-alpha-D-glucosaminase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016231; F:beta-N-acetylglucosaminidase activity; IDA:UniProtKB.
DR   GO; GO:0004415; F:hyalurononglucosaminidase activity; TAS:ProtInc.
DR   GO; GO:0006516; P:glycoprotein catabolic process; TAS:ProtInc.
DR   GO; GO:0009100; P:glycoprotein metabolic process; IBA:GO_Central.
DR   GO; GO:0006044; P:N-acetylglucosamine metabolic process; IDA:UniProtKB.
DR   GO; GO:0006517; P:protein deglycosylation; IDA:UniProtKB.
DR   GO; GO:0006493; P:protein O-linked glycosylation; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   DisProt; DP02479; -.
DR   IDEAL; IID00643; -.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR011496; Beta-N-acetylglucosaminidase.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   Pfam; PF07555; NAGidase; 1.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   SUPFAM; SSF55729; SSF55729; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Glycosidase;
KW   Host-virus interaction; Hydrolase; Nucleus; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..916
FT                   /note="Protein O-GlcNAcase"
FT                   /id="PRO_0000252118"
FT   REGION          278..280
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q2CEE3"
FT   ACT_SITE        175
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000305|PubMed:16533067"
FT   BINDING         67
FT                   /note="Substrate; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q2CEE3"
FT   BINDING         98
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q0TR53"
FT   BINDING         174
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q0TR53"
FT   BINDING         219
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q2CEE3"
FT   BINDING         285
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q2CEE3"
FT   BINDING         313
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q2CEE3"
FT   SITE            413..414
FT                   /note="Cleavage; by caspase-3"
FT                   /evidence="ECO:0000269|PubMed:18586680"
FT   MOD_RES         364
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   VAR_SEQ         346..398
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_020866"
FT   VAR_SEQ         663..677
FT                   /note="CRSHSSAQFLIGDQE -> RCTRNNLFSSNILSL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:9811929"
FT                   /id="VSP_020867"
FT   VAR_SEQ         678..916
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:9811929"
FT                   /id="VSP_020868"
FT   VAR_SEQ         691..704
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_020869"
FT   VARIANT         46
FT                   /note="G -> E (in dbSNP:rs3740421)"
FT                   /id="VAR_027761"
FT   VARIANT         602
FT                   /note="E -> K (in dbSNP:rs17853930)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_027762"
FT   MUTAGEN         69
FT                   /note="Y->K,Q: Strongly reduces affinity for glycopeptide
FT                   substrates. Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:20863279,
FT                   ECO:0000269|PubMed:22365600"
FT   MUTAGEN         69
FT                   /note="Y->S: Strongly reduces affinity for glycopeptide
FT                   substrates. Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:20863279,
FT                   ECO:0000269|PubMed:22365600"
FT   MUTAGEN         174
FT                   /note="D->A: Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:16533067"
FT   MUTAGEN         175
FT                   /note="D->A: Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:16533067"
FT   MUTAGEN         175
FT                   /note="D->N: Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:20863279"
FT   MUTAGEN         255
FT                   /note="V->G,T: Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:20863279"
FT   MUTAGEN         286
FT                   /note="Y->S: Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:20863279"
FT   MUTAGEN         287
FT                   /note="D->A: Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:20863279"
FT   MUTAGEN         413
FT                   /note="D->A: Abrogates cleavage by caspase-3."
FT                   /evidence="ECO:0000269|PubMed:18586680"
FT   MUTAGEN         679
FT                   /note="W->N: Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:20863279"
FT   TURN            50..52
FT                   /evidence="ECO:0000244|PDB:6PM9"
FT   TURN            54..57
FT                   /evidence="ECO:0000244|PDB:5UHP"
FT   STRAND          61..66
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          69..71
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           75..87
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          92..95
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           101..103
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            104..108
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           113..128
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          132..137
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            140..142
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           148..162
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            163..165
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          168..172
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           182..187
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          188..190
FT                   /evidence="ECO:0000244|PDB:5VVU"
FT   HELIX           191..205
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          212..215
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           221..223
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          224..226
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            228..230
FT                   /evidence="ECO:0000244|PDB:5M7R"
FT   HELIX           232..240
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          245..249
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          252..255
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           261..271
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          276..279
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           285..287
FT                   /evidence="ECO:0000244|PDB:5UHK"
FT   HELIX           301..306
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          308..312
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           318..321
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           322..332
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            334..337
FT                   /evidence="ECO:0000244|PDB:5UHL"
FT   HELIX           376..388
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            389..391
FT                   /evidence="ECO:0000244|PDB:5M7R"
FT   STRAND          542..544
FT                   /evidence="ECO:0000244|PDB:5M7T"
FT   HELIX           555..564
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           573..587
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           589..591
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            601..603
FT                   /evidence="ECO:0000244|PDB:6HKI"
FT   HELIX           605..628
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           634..661
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            662..666
FT                   /evidence="ECO:0000244|PDB:5M7R"
FT   TURN            680..683
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   HELIX           684..692
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            694..699
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   TURN            710..712
FT                   /evidence="ECO:0000244|PDB:5M7R"
SQ   SEQUENCE   916 AA;  102915 MW;  01F8A64A9B1475C6 CRC64;
     MVQKESQATL EERESELSSN PAASAGASLE PPAAPAPGED NPAGAGGAAV AGAAGGARRF
     LCGVVEGFYG RPWVMEQRKE LFRRLQKWEL NTYLYAPKDD YKHRMFWREM YSVEEAEQLM
     TLISAAREYE IEFIYAISPG LDITFSNPKE VSTLKRKLDQ VSQFGCRSFA LLFDDIDHNM
     CAADKEVFSS FAHAQVSITN EIYQYLGEPE TFLFCPTEYC GTFCYPNVSQ SPYLRTVGEK
     LLPGIEVLWT GPKVVSKEIP VESIEEVSKI IKRAPVIWDN IHANDYDQKR LFLGPYKGRS
     TELIPRLKGV LTNPNCEFEA NYVAIHTLAT WYKSNMNGVR KDVVMTDSED STVSIQIKLE
     NEGSDEDIET DVLYSPQMAL KLALTEWLQE FGVPHQYSSR QVAHSGAKAS VVDGTPLVAA
     PSLNATTVVT TVYQEPIMSQ GAALSGEPTT LTKEEEKKQP DEEPMDMVVE KQEETDHKND
     NQILSEIVEA KMAEELKPMD TDKESIAESK SPEMSMQEDC ISDIAPMQTD EQTNKEQFVP
     GPNEKPLYTA EPVTLEDLQL LADLFYLPYE HGPKGAQMLR EFQWLRANSS VVSVNCKGKD
     SEKIEEWRSR AAKFEEMCGL VMGMFTRLSN CANRTILYDM YSYVWDIKSI MSMVKSFVQW
     LGCRSHSSAQ FLIGDQEPWA FRGGLAGEFQ RLLPIDGAND LFFQPPPLTP TSKVYTIRPY
     FPKDEASVYK ICREMYDDGV GLPFQSQPDL IGDKLVGGLL SLSLDYCFVL EDEDGICGYA
     LGTVDVTPFI KKCKISWIPF MQEKYTKPNG DKELSEAEKI MLSFHEEQEV LPETFLANFP
     SLIKMDIHKK VTDPSVAKSM MACLLSSLKA NGSRGAFCEV RPDDKRILEF YSKLGCFEIA
     KMEGFPKDVV ILGRSL
//
